NASDAQ:KURA Kura Oncology (KURA) Stock Price, News & Analysis → Your Money is Not Safe (From American Alternative) (Ad) Free KURA Stock Alerts $21.33 +0.16 (+0.76%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$20.89▼$21.6550-Day Range$13.42▼$23.5352-Week Range$7.41▼$24.17Volume867,490 shsAverage Volume1.07 million shsMarket Capitalization$1.62 billionP/E RatioN/ADividend YieldN/APrice Target$28.28 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Kura Oncology alerts: Email Address Kura Oncology MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside32.6% Upside$28.28 Price TargetShort InterestHealthy16.21% of Float Sold ShortDividend StrengthN/ASustainability-0.76Upright™ Environmental ScoreNews Sentiment0.94Based on 2 Articles This WeekInsider TradingSelling Shares$1.95 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.35) to ($2.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.96 out of 5 starsMedical Sector191st out of 939 stocksPharmaceutical Preparations Industry82nd out of 443 stocks 3.4 Analyst's Opinion Consensus RatingKura Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $28.28, Kura Oncology has a forecasted upside of 32.6% from its current price of $21.33.Amount of Analyst CoverageKura Oncology has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted16.21% of the float of Kura Oncology has been sold short.Short Interest Ratio / Days to CoverKura Oncology has a short interest ratio ("days to cover") of 7.3.Change versus previous monthShort interest in Kura Oncology has recently decreased by 6.53%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldKura Oncology does not currently pay a dividend.Dividend GrowthKura Oncology does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKura Oncology has received a 73.98% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Kura Oncology is -0.76. Previous Next 2.7 News and Social Media Coverage News SentimentKura Oncology has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Kura Oncology this week, compared to 3 articles on an average week.Search InterestOnly 20 people have searched for KURA on MarketBeat in the last 30 days. This is a decrease of -23% compared to the previous 30 days.MarketBeat Follows8 people have added Kura Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kura Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,946,415.00 in company stock.Percentage Held by InsidersOnly 5.40% of the stock of Kura Oncology is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Kura Oncology are expected to decrease in the coming year, from ($2.35) to ($2.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kura Oncology is -10.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kura Oncology is -10.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKura Oncology has a P/B Ratio of 3.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad American AlternativeYour Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…CLICK HERE TO GET YOUR GUIDE NOW About Kura Oncology Stock (NASDAQ:KURA)Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.Read More KURA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KURA Stock News HeadlinesMarch 28, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Celcuity (CELC)March 7, 2024 | markets.businessinsider.comBuy Rating Affirmed: Kura Oncology’s KO-2806 Shows Promising Clinical and Market PotentialMarch 29, 2024 | American Alternative (Ad)Your Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…March 6, 2024 | finanznachrichten.deKura Oncology, Inc.: Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell CarcinomaMarch 6, 2024 | globenewswire.comKura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell CarcinomaMarch 1, 2024 | globenewswire.comKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 1, 2024 | markets.businessinsider.comBuy Rating for Kura Oncology Amid Strong Q4 Results and Promising Ziftomenib TrialsFebruary 28, 2024 | markets.businessinsider.comKura Oncology’s Ziftomenib Shows Promising Clinical Progress with Strong Market Potential and Buy RatingMarch 29, 2024 | American Alternative (Ad)Your Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…February 28, 2024 | finance.yahoo.comKURA Jul 2024 22.500 callFebruary 28, 2024 | markets.businessinsider.comBuy Rating for Kura Oncology: Promising Pipeline and Strategic Advantages Solidify Market PositionFebruary 28, 2024 | markets.businessinsider.comStrong Buy Rating for Kura Oncology Based on Solid Financials and Promising Clinical TrialsFebruary 28, 2024 | markets.businessinsider.comTD Cowen Sticks to Its Buy Rating for Kura Oncology (KURA)February 28, 2024 | finance.yahoo.comQ4 2023 Kura Oncology Inc Earnings CallFebruary 27, 2024 | seekingalpha.comKura Oncology, Inc. 2023 Q4 - Results - Earnings Call PresentationFebruary 27, 2024 | finance.yahoo.comKura Oncology Inc (KURA) Reports Q4 and Full Year 2023 Financial ResultsFebruary 27, 2024 | globenewswire.comKura Oncology Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 26, 2024 | globenewswire.comKura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid LeukemiaFebruary 25, 2024 | msn.comKura Oncology (KURA) Price Target Increased by 6.63% to 30.77February 22, 2024 | finance.yahoo.comKura Oncology to Participate in Three Upcoming Investor ConferencesFebruary 22, 2024 | globenewswire.comKura Oncology to Participate in Three Upcoming Investor ConferencesFebruary 20, 2024 | finance.yahoo.comKura Oncology to Report Fourth Quarter and Full Year 2023 Financial ResultsFebruary 20, 2024 | globenewswire.comKura Oncology to Report Fourth Quarter and Full Year 2023 Financial ResultsFebruary 17, 2024 | ca.finance.yahoo.comKURA Mar 2024 25.000 callFebruary 16, 2024 | finance.yahoo.comKURA Mar 2024 22.500 putFebruary 5, 2024 | ca.finance.yahoo.comKURA Mar 2024 30.000 callFebruary 2, 2024 | finance.yahoo.comKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)See More Headlines Receive KURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today3/29/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KURA CUSIPN/A CIK1422143 Webwww.kuraoncology.com Phone(858) 500-8800FaxN/AEmployees142Year FoundedN/APrice Target and Rating Average Stock Price Target$28.28 High Stock Price Target$37.00 Low Stock Price Target$10.50 Potential Upside/Downside+32.6%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-152,630,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-36.30% Return on Assets-33.12% Debt Debt-to-Equity Ratio0.02 Current Ratio12.26 Quick Ratio12.26 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.35 per share Price / Book3.99Miscellaneous Outstanding Shares76,140,000Free Float72,026,000Market Cap$1.62 billion OptionableOptionable Beta0.86 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Troy Edward Wilson J.D. (Age 55)Ph.D., Chairman, CEO & President Comp: $1.06MMs. Kathleen Ford (Age 77)Chief Operating Officer Comp: $754.24kDr. Stephen Dale M.D. (Age 52)Chief Medical Officer Comp: $684.41kMr. Thomas Doyle (Age 53)Senior Vice President of Finance & Accounting Mr. Pete De SpainExecutive Vice President of Investor Relations & Corporate CommunicationsMs. Teresa Brophy Bair Esq. (Age 53)J.D., Chief Legal Officer & Corporate Secretary Dr. Roger Bakale Ph.D.Senior Vice President of Manufacturing & Supply ChainMs. Maureen Clancy M.B.A.VP and Global Head of Program Leadership & Project ManagementDr. Mollie Leoni M.D.Executive Vice President of Clinical DevelopmentMr. Brian T. Powl M.B.A. (Age 50)M.S., Chief Commercial Officer More ExecutivesKey CompetitorsZai LabNASDAQ:ZLABTaro Pharmaceutical IndustriesNYSE:TAROArcus BiosciencesNYSE:RCUSEdgewise TherapeuticsNASDAQ:EWTXDynavax TechnologiesNASDAQ:DVAXView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 113,243 shares on 3/11/2024Ownership: 5.303%Wellington Management Group LLPBought 56,363 shares on 3/5/2024Ownership: 0.074%Goldman Sachs Group Inc.Bought 70,765 shares on 3/1/2024Ownership: 0.698%Price T Rowe Associates Inc. MDSold 17,659 shares on 2/16/2024Ownership: 0.023%Virtus ETF Advisers LLCSold 877 shares on 2/15/2024Ownership: 0.010%View All Insider TransactionsView All Institutional Transactions KURA Stock Analysis - Frequently Asked Questions Should I buy or sell Kura Oncology stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" KURA shares. View KURA analyst ratings or view top-rated stocks. What is Kura Oncology's stock price target for 2024? 8 equities research analysts have issued 12-month price objectives for Kura Oncology's shares. Their KURA share price targets range from $10.50 to $37.00. On average, they anticipate the company's stock price to reach $28.28 in the next twelve months. This suggests a possible upside of 32.6% from the stock's current price. View analysts price targets for KURA or view top-rated stocks among Wall Street analysts. How have KURA shares performed in 2024? Kura Oncology's stock was trading at $14.38 on January 1st, 2024. Since then, KURA stock has increased by 48.3% and is now trading at $21.33. View the best growth stocks for 2024 here. When is Kura Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our KURA earnings forecast. How were Kura Oncology's earnings last quarter? Kura Oncology, Inc. (NASDAQ:KURA) posted its earnings results on Tuesday, February, 27th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.01. During the same quarter last year, the business posted ($0.49) EPS. What ETF holds Kura Oncology's stock? Simplify Propel Opportunities ETF holds 80,000 shares of KURA stock, representing 0.79% of its portfolio. What other stocks do shareholders of Kura Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD). Who are Kura Oncology's major shareholders? Kura Oncology's stock is owned by a number of retail and institutional investors. Top institutional investors include BVF Inc. IL (9.68%), Vanguard Group Inc. (5.30%), Vanguard Group Inc. (5.30%), Armistice Capital LLC (2.99%), Dimensional Fund Advisors LP (2.70%) and Franklin Resources Inc. (1.82%). Insiders that own company stock include Kathleen Ford, Kirsten Flowers, Teresa Brophy Bair, Thomas James Doyle, Thomas Malley and Troy Edward Wilson. View institutional ownership trends. How do I buy shares of Kura Oncology? Shares of KURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KURA) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeYour Money is Not SafeAmerican AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaOnly a fool would buy Nvidia today… Porter & CompanyThe ONE AI Sock to own now. (It’s not Nvidia.)Weiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kura Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.